NASDAQ: NUVLNuvalent Inc Stock
$100.59+0.21 (+0.21%)
Updated Dec 31, 2025
NUVL Price
$100.59
Fair Value Price
$2.19
Market Cap
$7.31B
52 Week Low
$55.54
52 Week High
$112.88
P/E
-18.87x
P/B
8.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$381.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.16
Operating Cash Flow
-$264M
Beta
1.49
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NUVL Overview
Nuvalent, Inc. is developing cancer therapies meant to overcome the limitations of existing therapies for clinically proven kinase targets. Its lead product candidate, NVL-520, is a brain-penetrant ROS1-selective inhibitor. Nuvalent was incorporated in 2017 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NUVL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NUVL
Ranked#298 of 490
Ranked#298 of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $17.67 | A | |
| $15.95 | A | |
| $397.65 | A |
Be the first to know about important NUVL news, forecast changes, insider trades & much more!
NUVL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NUVL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NUVL ($100.59) is overvalued by 4,485.1% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NUVL ($100.59) is not significantly undervalued (4,485.1%) relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NUVL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NUVL due diligence checks available for Premium users.
Valuation
NUVL fair value
Fair Value of NUVL stock based on Discounted Cash Flow (DCF)
Price
$100.59
Fair Value
$2.19
Overvalued by
4,485.10%
NUVL ($100.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NUVL ($100.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NUVL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NUVL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.87x
Industry
146.65x
Market
43.85x
NUVL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.65x
Industry
5.25x
NUVL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NUVL's financial health
Profit margin
Revenue
$0.0
Net Income
-$122.4M
Profit Margin
0%
NUVL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$979.9M
Liabilities
$134.5M
Debt to equity
0.16
NUVL's short-term assets ($956.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NUVL's short-term assets ($956.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NUVL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$70.5M
Investing
$54.0M
Financing
$4.8M
NUVL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NUVL vs Biotech Stocks
Nuvalent Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.